PMID- 29349927
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20181202
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 14
IP  - 3
DP  - 2018 Jun
TI  - Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: 
      A meta-analysis.
PG  - 141-152
LID - 10.1111/ajco.12838 [doi]
AB  - BACKGROUND: We performed a meta-analysis to quantify toxic death, adverse events 
      (AEs) and treatment discontinuation due to AEs from checkpoint inhibitors (CI). 
      METHODS: We searched for randomized trials with adequate reporting for toxicity 
      outcomes. Pooled risk ratios were estimated for CI versus chemotherapy or 
      different combinations of these agents. RESULTS: Twenty trials of five different 
      cancers with 10 794 patients with performance status 0 or 1 were identified. 
      Toxic deaths from CI were infrequent (0.6%). Treatment discontinuations were less 
      frequent for programmed-death-1 (PD-1) or PD-ligand-1 (PD-L1) inhibitors (5.8% vs 
      13.3%, P < 0.001) and cytotoxic-T-lymphocyte-associated-antigen-4 (CTLA-4) 
      inhibitors (6.2% vs 11.4%, P = 0.002) than chemotherapy. PD-1/PD-L1 inhibitors 
      had less grade 3, 4, and 5 (G3/4/5) AEs than chemotherapy (13.8% vs 39.8%, P < 
      0.001) or CTLA-4 inhibitors (13.4% vs 22.8%, P < 0.001). Combination CI had 
      higher discontinuation (37.8% vs 11.6%, P < 0.001) and higher G3/4/5 AEs (55.3% 
      vs 21.9%, P < 0.001) than CI monotherapy. Endocrinopathy (11.2% vs 0.9%), rash 
      (10.1% vs 4.3%) and pneumonitis (3.1% vs 0.7%) were associated with CI, and 
      alopecia (25.9% vs 1.0%), neutropenia (16.6% vs 0.6%) and neuropathy (7.6% vs 
      3.0%) with chemotherapy. CONCLUSIONS: CI inhibitors have different toxicity 
      profiles to chemotherapy. These findings are useful for patient counselling and 
      planning of future trials.
CI  - (c) 2018 John Wiley & Sons Australia, Ltd.
FAU - Man, Johnathan
AU  - Man J
AUID- ORCID: 0000-0002-8505-1506
AD  - Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, 
      Australia.
FAU - Ritchie, Georgia
AU  - Ritchie G
AD  - Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, 
      Australia.
AD  - School of Medicine, University of New South Wales, High St, Kensington, NSW, 
      Australia.
FAU - Links, Matthew
AU  - Links M
AD  - Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, 
      Australia.
FAU - Lord, Sally
AU  - Lord S
AD  - National Health and Medical Research Council Clinical Trials Centre, The 
      University of Sydney, Camperdown, NSW, Australia.
AD  - School of Medicine, The University of Notre Dame, Oxford St, Darlinghurst, NSW, 
      Australia.
FAU - Lee, Chee Khoon
AU  - Lee CK
AD  - Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, 
      Australia.
AD  - National Health and Medical Research Council Clinical Trials Centre, The 
      University of Sydney, Camperdown, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180119
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
CIN - Asia Pac J Clin Oncol. 2019 Jun;15(3):191. PMID: 30815961
MH  - Antibodies, Monoclonal/*adverse effects/pharmacology
MH  - Antineoplastic Agents/*adverse effects/pharmacology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/*drug therapy/pathology
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
OTO - NOTNLM
OT  - PD-1 blockade
OT  - cancer
OT  - chemotherapy
OT  - immunotherapy
OT  - toxicity
EDAT- 2018/01/20 06:00
MHDA- 2018/07/25 06:00
CRDT- 2018/01/20 06:00
PHST- 2017/05/07 00:00 [received]
PHST- 2017/11/18 00:00 [accepted]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - 10.1111/ajco.12838 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2018 Jun;14(3):141-152. doi: 10.1111/ajco.12838. Epub 2018 
      Jan 19.